サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1526338

生体吸収性ステントの世界市場

Bioresorbable Stents

出版日
ページ情報
英文 125 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
生体吸収性ステントの世界市場
出版日: 2024年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 125 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

生体吸収性ステントの世界市場は2030年までに12億米ドルに達する見込み

2023年に5億5,440万米ドルと推定される生体吸収性ステントの世界市場は、2030年には12億米ドルに達し、分析期間2023-2030年のCAGRは12.1%で成長すると予測されます。ポリマーベースの生体吸収性ステントは、本レポートで分析したセグメントの1つであり、CAGR 12.8％を記録し、分析期間終了時には9億520万米ドルに達すると予測されています。金属ベースの生体吸収性ステント分野の成長率は、分析期間中CAGR 10.2%と推定されます。

世界の生体吸収性ステント市場動向と促進要因まとめ

生体吸収性血管足場（BVS）としても知られる生体吸収性ステントは、インターベンショナル心臓病学における重要な進歩を象徴しています。これらのステントは、手技後に動脈を一時的に支持し、時間の経過とともに徐々に溶解して自然な血管を残すように設計されています。体内に永久に残る従来の金属製ステントとは異なり、生体吸収性ステントはポリ乳酸（PLA）のような、自然に分解して体内に吸収される材料で構成されています。この一時的な性質により、慢性炎症や後期血栓症など、永久的なインプラントに伴う長期的なリスクが軽減されます。臨床試験では、生体吸収性ステントが冠動脈疾患の治療に有効であることが実証されており、金属製ステントに匹敵する結果を示すとともに、時間の経過とともに血管本来の機能と柔軟性を回復させるという利点もあります。

生体吸収性ステントの開発は、広範な研究と技術革新によって推進されてきました。これらのステントは、血管形成術後の重要な治癒期間中、動脈に必要な機械的支持を与えるように設計されています。時間の経過とともにステントは徐々に劣化し、長期的な合併症のリスクを軽減します。さらに、生体吸収性ステントはしばしば抗増殖薬でコーティングされ、再狭窄、すなわち動脈の再狭窄をさらに防止します。機械的支持とドラッグデリバリーの二重機能により、患者の治療成績が向上します。さらに、高度な画像処理技術と精密工学の使用により、これらのステントの配備と有効性が改善され、より幅広い患者や臨床場面で実行可能な選択肢となっています。

生体吸収性ステント市場の成長は、いくつかの要因によってもたらされます。第一に、世界的に心血管疾患、特に冠動脈疾患の有病率が増加しており、効果的で革新的な治療オプションが必要とされています。第二に、患者やヘルスケアプロバイダーの間で低侵襲処置に対する需要が高まっていることが、生体吸収性ステントの採用に拍車をかけています。これらのステントは従来の方法に代わる有望な選択肢を提供し、より低侵襲な介入を目指す傾向に合致しています。第三に、生体材料とステント設計の技術的進歩が生体吸収性ステントの性能と安全性を高め、臨床医にとってより魅力的なものになっています。最後に、これらのステントに対する患者の認識と受容の高まりが、いくつかの地域における有利な償還政策と相まって、市場の成長をさらに後押ししています。これらの要因が重なることで、現代の心血管治療パラダイムにおける生体吸収性ステントの役割が拡大していることが裏付けられています。

調査対象企業の例（注目の25社）

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Eurocor GmbH
  • Biosensors International Group Ltd.
  • Elixir Medical Corporation
  • InSitu Technologies, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • Medinol Ltd.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim A.S.
  • Meril Life Sciences Pvt., Ltd.
  • Arterial Remodeling Technologies SA
  • iVascular S.L.U
  • Endocor GmbH

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 世界市場概要
  • 市場見通し
  • 競合
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP10697

Global Bioresorbable Stents Market to Reach US$1.2 Billion by 2030

The global market for Bioresorbable Stents estimated at US$554.4 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2023-2030. Polymer-based Bioresorbable Stents, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$905.2 Million by the end of the analysis period. Growth in the Metal-based Bioresorbable Stents segment is estimated at 10.2% CAGR over the analysis period.

Global Bioresorbable Stents Market - Key Trends & Drivers Summarized

Bioresorbable stents, also known as bioresorbable vascular scaffolds (BVS), represent a significant advancement in interventional cardiology. These stents are designed to provide temporary support to the artery after a procedure, gradually dissolving over time and leaving behind a natural vessel. Unlike traditional metal stents, which remain permanently in the body, bioresorbable stents are composed of materials like polylactic acid (PLA) that naturally break down and are absorbed by the body. This temporary nature reduces the long-term risks associated with permanent implants, such as chronic inflammation and late-stage thrombosis. Clinical trials have demonstrated the efficacy of bioresorbable stents in treating coronary artery disease, showing comparable outcomes to metallic stents with the added benefit of restoring the vessel's natural function and flexibility over time.

The development of bioresorbable stents has been propelled by extensive research and technological innovations. These stents are engineered to provide the necessary mechanical support to the artery during the critical healing period post-angioplasty. Over time, the stent gradually degrades, reducing the risk of long-term complications. Additionally, bioresorbable stents are often coated with antiproliferative drugs to further prevent restenosis, or re-narrowing of the artery. This dual function of providing mechanical support and drug delivery enhances the therapeutic outcomes for patients. Furthermore, the use of advanced imaging techniques and precision engineering has improved the deployment and efficacy of these stents, making them a viable option for a broader range of patients and clinical scenarios.

The growth in the bioresorbable stents market is driven by several factors. Firstly, there is an increasing prevalence of cardiovascular diseases globally, particularly coronary artery disease, which necessitates effective and innovative treatment options. Secondly, the rising demand for minimally invasive procedures among patients and healthcare providers is fueling the adoption of bioresorbable stents. These stents offer a promising alternative to traditional methods, aligning with the trend towards less invasive interventions. Thirdly, technological advancements in biomaterials and stent design are enhancing the performance and safety profile of bioresorbable stents, making them more attractive to clinicians. Lastly, the growing awareness and acceptance of these stents among patients, coupled with favorable reimbursement policies in several regions, are further boosting market growth. The confluence of these factors underscores the expanding role of bioresorbable stents in modern cardiovascular treatment paradigms.

Select Competitors (Total 25 Featured) -

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Eurocor GmbH
  • Biosensors International Group Ltd.
  • Elixir Medical Corporation
  • InSitu Technologies, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • Medinol Ltd.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim A.S.
  • Meril Life Sciences Pvt., Ltd.
  • Arterial Remodeling Technologies SA
  • iVascular S.L.U
  • Endocor GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Bioresorbable Stents - Global Key Competitors Percentage Market Share in 2024 (E)
    • Coronary Artery Disease (CAD) - A Perspective
    • Causes and Symptoms
    • Treatment Options for Coronary Artery Disease
    • Percutaneous Coronary Intervention (PCI)
    • Coronary Stenting
    • Types of Coronary Stents
    • Bare Metal Stents (BMS)
    • Drug Eluting Stents (DES)
    • Bioresorbable Scaffolds
    • Design and Composition of Bioresorbable Scaffolds
    • Different Types of Bioresorbable Scaffolds
    • Metallic Bioresorbable Scaffolds
    • Polymer Bioresorbable Scaffolds
    • Degradation Period of Select Bioabsorbable Materials
    • Challenges
    • Clinical Characteristics of Various Coronary Stents
    • Other Treatment Options for Coronary Heart Disease
    • Coronary Artery Bypass Grafting (CABG)
    • Minimally Invasive Direct Coronary Artery Bypass (MIDCAB)
    • TransMyocardial Laser Revascularization (TMR)
    • Peripheral Arterial Disease: Understanding the Stealthy Peril
    • Treatment for PAD
    • Stenting- A Treatment Option for PAD
    • BioResorbable Stents - A Prelude
    • Bioresorbable Vascular Scaffolds: Advantages and Challenges
    • Bioresorbable Stents - A Revolutionary Technology, Riddled with Controversies
    • Abbott Stops Sales of the Once Promising 'Absorb' Bioresorbable Stents due to Adverse Events
    • Impact of Abbott's Withdrawal of Absorb on the Bioresorbable Stent Industry
  • GLOBAL MARKET OVERVIEW
    • Global Bioresorbable Stents Set to Witness Growth in Future
    • Europe Dominates, Asia-Pacific Exhibits Fastest Growth
    • CAD Constitutes the Leading Application
    • Metallic Vs. Polymer-based Stents
    • Bioabsorbable Metallic Stents
    • Bioabsorbable Polymer Stents
    • Disappointing Results by Absorb to Increase Focus on Metallic Stents
    • Availability of Alternative Treatments - Hindrance to Market Growth
    • Market Challenges
  • MARKET OUTLOOK
    • Bioresorbable and Integrated Biosensor Technology to Redefine Future of Vascular Stents
    • The Future of BRS Technology
  • COMPETITION
    • Select Approved Bioresorbable Scaffolds
    • Select Bioresorbable Stents in Pipeline
    • Abbott Revives Bioresorbable Stent Clinical Trials to Evaluate New Esprit Scaffold
    • Recent Market Activity
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Polymeric Resorbable Scaffolds Hold a Major Market Share
    • The Absorb BRS program
    • Desaminotyrosine Polycarbonate-based BRS
    • The FANTOM program
    • Magnesium-based BRS
    • The Magmaris program
    • Iron-based BRS
    • Global Menace of Coronary Artery Disease (CAD) - A Major Growth Driver
    • Global Annual Medical Cost of CVD in the United States: 2015-2030
    • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Ageing Demographics and Longer Life Expectancy Bolsters Market Growth
    • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Rising Middle Class Population Aids Growth
    • Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P
    • Rising Healthcare Expenditure: Opportunities in Store
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Risk of CAD in Obesity Offers Prospects for Coronary Stenting
    • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Diabetics at Higher Risk of Heart Diseases
    • TABLE 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040
    • The Hypertension-Cholesterol Link to Drive Demand
    • Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years
    • Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
    • Metal Stents Vis-a-Vis Other Stents
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Bioresorbable Stents by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Bioresorbable Stents by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Metal-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Metal-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Coronary Artery Disease/CAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Coronary Artery Disease/CAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Peripheral Artery Disease/PAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Peripheral Artery Disease/PAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cardiovascular Centers by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World 7-Year Perspective for Cardiovascular Centers by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 15: World Bioresorbable Stents Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030

III. MARKET ANALYSIS

  • EUROPE
    • Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 16: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: Europe 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 18: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Europe 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 20: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Europe 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 22: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 24: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 28: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of World 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 30: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Rest of World 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 32: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Rest of World 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030

IV. COMPETITION